secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001178913-25-001909
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics completes preclinical studies of SIL204 in KRAS-driven colorectal, lung, and pancreatic cancers
--------------------------------------------------------------------------------

- SIL204 evaluated in GP2D (colorectal), A427 (lung), and Panc-1 (pancreatic) KRAS-mutant cell lines.
- Company expects to announce comprehensive results within the next few days.
- If positive, SIL204 could expand development strategy beyond pancreatic cancer.
- Global treatment markets for these three KRAS-driven cancers estimated at over $30 billion annually.
- KRAS mutations drive ~90% of pancreatic, ~45% of colorectal, and ~35% of non-squamous NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/0001178913-25-001909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325001909/zk2533232.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-001909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer